Galapagos promotes Piet Wigerinck to CSO
This article was originally published in Scrip
Executive Summary
Galapagos has named Dr Piet Wigerinck chief scientific officer, responsible for overseeing target and drug discovery efforts and expanding the company's development department. Dr Wigerinck joined Galapagos as senior vice-president of development in April 2008, and before that was vice-president of drug discovery, early development and CM&C at Tibotec.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.